Company intelligence / Profile preview

Xylo Bio

Boulder, Colorado, United Statespsylofashion.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

PSYLO-100X, the company's flagship non-hallucinogenic 5-HT2A agonist, has shown antidepressant-like effects in living organisms and fosters neuroplasticity in vitro, while avoiding activation at the 5-HT2B receptor to prevent cardiotoxicity risk. The company plans to advance to first-in-human clinical trials in 2025.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculesNeuroplastogens
Industry: Biotech

Drug pipeline

1 asset

PSYLO-100X

Pre-clinical

Indications: Depression, Anxiety, Post-traumatic stress disorder

Partnerships

Global pharmaceutical companies

Beyond the preview

Go deeper on Xylo Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xylo Bio.

Explore the full profile